Biotechnology

#Assays #Biotechnology #Drug discovery #Enzymes #TechNote

TechNote: Radioactivity assays for methyltransferase enzymes

In this free TechNote by SAMDI Tech, learn how the company’s radioactivity assays overcome key challenges in drug discovery by offering key solutions, including: Detecting low amounts of product with sensitive assays Generating data rapidly with high-throughput, 384-well capabilities Characterising potent inhibitors by benefiting from lower enzyme concentrations Learn… Read More

#News #Trending News

#Antibodies #Biotechnology #Collaboration #Neurodegenerative disorders #Neuroscience

Neurodegenerative collaboration seeks novel drug candidates 

Neurimmune has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical, which is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilising Neurimmune’s proprietary Reverse Translational Medicine (RTM) technology platform, an antibody drug creation approach.  Background  In November 2017, Ono and Neurimmune signed… Read More

#News

#Biomarkers #Biopharmaceuticals #Biotechnology #Funding

€13.5m financing round to accelerate proteomics tools and consumables 

PreOmics has raised €13.5 million in a Series B financing round provided by Bruker Corporation, which is expected to broaden the market opportunities for both PreOmics’ platform technologies and Bruker’s  proteomics platform with more complete, automated workflow solutions for academic and clinical researchers, for biomarker discovery and diagnostics companies, as well as for… Read More

#News

#Biotechnology #Life sciences #Therapeutics

PhoreMost expands into new facility  

PhoreMost it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, designed to support PhoreMost’s phenotypic screening requirements and expertise. The new facility enables the company to add in-house flow cytometry and imaging capabilities.  Dr Chris Torrance, CEO of PhoreMost, said: “Our move to Unity Campus follows… Read More

#News

#Biotechnology #Biotherapeutics

Nuclera announces expansion with new US subsidiary 

Nuclera, a UK-based biotech company, has opened a US subsidiary located in Boston, MA. This is designed to push Nuclera’s eProtein desktop bioprinter for biotherapeutics.  Dr Michael Chen, CEO and cofounder of Nuclera, said: “This site opening just outside one of the most important biotech markets is a big step towards Nuclera’s goal… Read More

#News

#Biotechnology #Lab automation

A new era for automated liquid handling 

Laboratories across the biotech and pharmaceutical industries are increasingly automating their liquid handling and dispensing capabilities with versatile, scalable, and affordable instruments that cater to a range of applications. This paid-for advertorial by SPT Labtech appeared in the DDW / SLAS supplement in DDW Volume 23, Issue 1 – Winter 2021/22.  The main benefits of… Read More

#Exclusive Content #News #Sponsored Content

#Biotechnology #Drug discovery #Therapeutics

Drug discovery movers: who’s going where? 

The new year is underway and with it comes a raft of movement within some of the industry’s key businesses. DDW’s Megan Thomas rounds up seven new additions to the sector.  Dr Charles Woler (Sygnature Discovery, UK)  Sygnature Discovery, provider of drug discovery solutions, has appointed Dr Charles Woler as Chairman. Dr Woler has… Read More

#News #Trending News

#Biotechnology #Clinical trials #Drug development #Tumours

Avacta takes step to increase the tolerability of chemotherapies  

Avacta has added the next pre|CISION drug candidate to its portfolio. AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023.  The technology  Avacta’s chemistry is used to modify chemotherapy drugs to render them inactive… Read More

#News

#Biotechnology #CRISPR #Life sciences #Microfluidics

Advances in automated genome engineering 

Olivia Hughes from Sphere Fluidics discusses how advances in picodroplet microfluidics, combined with the high efficiency of CRISPR/Cas9 technology, are fuelling a new wave of innovation in the form of a simple click-through workflow for genome editing.  Picodroplet microfluidics is rapidly becoming the technology of choice for high-throughput single cell analysis, providing an easy-to-use tool to… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#AI / data analytics / healthtech / informatics #Biotechnology #Database #Drug development #R&D #Research

Bridging the gap between R&D teams in biotechnology   

Ashu Singhal, President & Co-Founder of Benchling, shares newly heightened expectations for the biotechnology industry following the developments of the last 18 months.   The last 18 months have heightened expectations for the biotechnology industry. Scientists came together to develop vaccines at record speeds and set the… Read More

#News

#Biologics #Biotechnology #Pharmaceuticals #Research

Sino Biological establishes new location in Texas 

Sino Biological, provider of biological research reagents and related technical contract research services, has expanded to a new location in Houston, Texas.  The company has headquarters in Beijing, China and subsidiaries in Suzhou (China), Taizhou (China), Frankfurt (Germany), and Wayne (Pennsylvania, US). The new location in Houston allows for… Read More

#News

Artificial Intelligence
#AI / data analytics / healthtech / informatics #Biotechnology #Drug discovery #Drug targets

Collaboration to use AI for drug design and retrosyntheis 

The Drug Discovery Unit (DDU) in the School of Life Sciences at The University of Dundee is using Iktos’ generative modelling artificial intelligence (AI) technology in one of its drug discovery programmes.  The collaboration   Iktos will apply its de novo ligand and structure-based generative modelling technologies, its AI-based… Read More

#News

Seed funding
#Biotechnology #Pharmaceuticals

CSL to acquire Vifor Pharma

Global biotechnology company CSL Limited has launched a public tender offer to acquire all publicly held Vifor Pharma shares.  “Vifor Pharma enhances CSL’s patient focus and ability to protect the health of those facing a range of rare and serious medical conditions. It brings an outstanding team and a leading portfolio… Read More

#News

#Biotechnology #Microbiome #Neuroscience

Gut-brain research could result in improved cognitive performance 

In a collaborative project funded by the Next Generation Technologies Fund, researchers from the University of Newcastle and Queensland University of Technology in Australia will investigate the human, microbial and environmental interactions that affect cognitive performance, coined the ‘cognobiome’, by analysing the gut microbiome of soldiers.  The study … Read More

#News

#Biotechnology #Clinical trials #Drug design #Drug development #Rare disease #Therapeutics

Inside the rare disease centre which aims to accelerate biotech growth 

Emmes has launched a rare disease centre, Orphan Reach, to combine its health research across the public sector and biopharmaceutical industry. DDW’s Megan Thomas spoke with Thomas Ogorka, Managing Director of Orphan Reach: Emmes’ Rare Disease Center, about its potential.  MT: What will the expanded Orphan Reach centre add to what Emmes already offers?   TO: First and foremost, specialised rare… Read More

#Exclusive Content #News #Opinion

#Biomedical research #Biotechnology #Immunology

Spatial biology imaging platform dedicated to skin

Genoskin, a biotechnology company using live ex vivo human skin to test therapeutic and non-therapeutic products, has launched Mantis, a new spatial biology imaging platform dedicated to skin immunology. This new offer was developed by Genoskin’s recently appointed CSO Dr. Nicolas Gaudenzio and his team at Inserm.   What is Mantis?  … Read More

#News